Compared to small molecule inhibitors, the novel CRISPR/Cas9‐gene editing approach has a great potential for future personalized therapy in treating ABCB1‐associated MDR colorectal cancer with an advantage to avoid drug‐drug interaction and toxicity from combinational chemotherapy. The gene discussed is ABCB1; the disease is colorectal cancer.